| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH |
From Division of Obstetrics, Neonatology, and Gynecology and Division of Pediatric Endocrinology, University Medical Center Utrecht, Utrecht, The Netherlands; and Central Laboratory, Blood-Transfusion of the Red Cross, Amsterdam, The Netherlands.
Address reprint requests to: Godelieve C. M. L. Christiaens, MD, PhD, University Medical Center Utrecht, KE 04.123.1, PO Box 85090, 3508 AB Utrecht, The Netherlands; E-mail: l.christiaens{at}azu.nl.
OBJECTIVE: To determine first-trimester fetal sex by isolating free fetal DNA from maternal plasma.
METHODS: The index case was a pregnant woman who previously delivered a girl with congenital adrenal hyperplasia. The SRY gene as a marker for the fetal Y chromosome was detected in maternal serum and plasma by quantitative polymerase chain reaction analysis. Simultaneously, we performed the same test in 25 and 19 women in the first and second trimester, respectively, and compared plasma results with fetal gender as assessed by prenatal karyotyping or as seen at ultrasound or birth.
RESULTS: In 44 of 45 patients at gestational ages ranging from 8 3/7 to 17 3/7 weeks, we correctly predicted fetal sex using quantitative polymerase chain reaction analysis of the SRY gene in maternal plasma. In one case, the test result was inconclusive. Overall, fetal sex was correctly predicted in 97.8% of cases (95% confidence interval 88.2%, 99.9%).
CONCLUSION: Amplification of free fetal DNA in maternal plasma is a valid technique for predicting fetal sex in early pregnancy. In case of pregnancies at risk for congenital adrenal hyperplasia, the technique allows restriction of dexamethasone treatment to female fetuses resulting in a substantial decrease of unnecessary treatment and invasive diagnostic tests.
This article has been cited by other articles:
|
|
 |
|
  I. Stanghellini, R. Bertorelli, L. Capone, V. Mazza, C. Neri, A. Percesepe, and A. Forabosco Quantitation of fetal DNA in maternal serum during the first trimester of pregnancy by the use of a DAZ repetitive probe Mol. Hum. Reprod., September 1, 2006; 12(9): 587 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Zimmermann, A. El-Sheikhah, K. Nicolaides, W. Holzgreve, and S. Hahn Optimized Real-Time Quantitative PCR Measurement of Male Fetal DNA in Maternal Plasma Clin. Chem., September 1, 2005; 51(9): 1598 - 1604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.M. D. Lo Recent Advances in Fetal Nucleic Acids in Maternal Plasma J. Histochem. Cytochem., March 1, 2005; 53(3): 293 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Benachi, A. Yamgnane, M. Olivi, Y. Dumez, E. Gautier, and J.-M. Costa Impact of Formaldehyde on the in Vitro Proportion of Fetal DNA in Maternal Plasma and Serum Clin. Chem., January 1, 2005; 51(1): 242 - 244. [Full Text] [PDF]
|
|
|
|
|
|
R. J.P. Rijnders, G. C.M.L. Christiaens, A. A. Soussan, C. E. van der Schoot, P. Invernizzi, G. Simoni, and M. Podda Cell-Free Fetal DNA Is Not Present in Plasma of Nonpregnant Mothers * Authors of the article cited above respond: Clin. Chem., March 1, 2004; 50(3): 679 - 681. [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. P. Rijnders, G. C. M. L. Christiaens, B. Bossers, J. J. van der Smagt, C. E. van der Schoot, and M. de Haas Clinical Applications of Cell-Free Fetal DNA From Maternal Plasma Obstet. Gynecol., January 1, 2004; 103(1): 157 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Guibert, A. Benachi, A.-G. Grebille, P. Ernault, J.-R. Zorn, and J.-M. Costa Kinetics of SRY gene appearance in maternal serum: detection by real time PCR in early pregnancy after assisted reproductive technique Hum. Reprod., August 1, 2003; 18(8): 1733 - 1736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Bartha, K. Finning, and P. W. Soothill Fetal Sex Determination From Maternal Blood at 6 Weeks of Gestation When at Risk for 21-Hydroxylase Deficiency Obstet. Gynecol., May 1, 2003; 101(5): 1135 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Tachdjian, N. Frydman, F. Audibert, P. Ray, V. Kerbrat, P. Ernault, R. Frydman, and J.-M. Costa Clinical applications of fetal sex determination in maternal blood in a preimplantation genetic diagnosis centre Hum. Reprod., August 1, 2002; 17(8): 2183 - 2186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Bianchi Prenatal Exclusion of Recessively Inherited Disorders: Should Maternal Plasma Analysis Precede Invasive Techniques? Clin. Chem., May 1, 2002; 48(5): 689 - 690. [Full Text] [PDF]
|
|
|
|
|
|
R. W.K. Chiu, T. K. Lau, P. T. Cheung, Z. Q. Gong, T. N. Leung, and Y.M. D. Lo Noninvasive Prenatal Exclusion of Congenital Adrenal Hyperplasia by Maternal Plasma Analysis: A Feasibility Study Clin. Chem., May 1, 2002; 48(5): 778 - 780. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Moritz, A. Butkus, V. Hantzis, A. Peers, E. M. Wintour, and M. Dodic Prolonged Low-Dose Dexamethasone, in Early Gestation, Has No Long-Term Deleterious Effect on Normal Ovine Fetuses Endocrinology, April 1, 2002; 143(4): 1159 - 1165. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
